ETTX - エンタシス・セラピュ―ティクス （Entasis Therapeutics Holdings Inc.）

In a development that’s garnering attention in the healthcare sector, La Jolla Pharmaceutical (NASDAQ: LJPC ) has reportedly consented to be acquired by Innovia (NASDAQ: INVA ). As a result, LJPC stock soon likely won’t be listed on the Nasdaq exchange, or any public market for that matter. It’s not hard to figure out why Innovia would want to own La Jolla’s assets. La Jolla already has multiple regulatory wins under its belt. In 2017, the Food and Drug Administration (FDA) approved GIAPREZA , La Jolla’s lead product, to increase blood pressure in adults with septic or other distributive shock. Also, in 2018 the FDA approved La Jolla subsidiary Tetraphase’s XERAVA to treat complicated intra-abdominal infections in patients 18 years of age and older. Thus, acquiring La Jolla Pharmaceutical will help Innovia strengthen its infectious-diseases portfolio. Apparently, Innovia was already moving in this direction through its recent purchase of Entasis Therapeutics, which develops novel antibacterial products.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022.

In a development that’s garnering attention in the healthcare sector, La Jolla Pharmaceutical (NASDAQ: LJPC ) has reportedly consented to be acquired by Innovia (NASDAQ: INVA ). As a result, LJPC stock soon likely won’t be listed on the Nasdaq exchange, or any public market for that matter. It’s not hard to figure out why Innovia would want to own La Jolla’s assets. La Jolla already has multiple regulatory wins under its belt. In 2017, the Food and Drug Administration (FDA) approved GIAPREZA , La Jolla’s lead product, to increase blood pressure in adults with septic or other distributive shock. Also, in 2018 the FDA approved La Jolla subsidiary Tetraphase’s XERAVA to treat complicated intra-abdominal infections in patients 18 years of age and older. Thus, acquiring La Jolla Pharmaceutical will help Innovia strengthen its infectious-diseases portfolio. Apparently, Innovia was already moving in this direction through its recent purchase of Entasis Therapeutics, which develops novel antibacterial products.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022.

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Innoviva, Inc. (NASDAQ: INVA).

Innoviva Inc (NASDAQ: INVA ) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis'' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire … Full story available on Benzinga.com

GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%.

In a development that’s garnering attention in the healthcare sector, La Jolla Pharmaceutical (NASDAQ: LJPC ) has reportedly consented to be acquired by Innovia (NASDAQ: INVA ). As a result, LJPC stock soon likely won’t be listed on the Nasdaq exchange, or any public market for that matter. It’s not hard to figure out why Innovia would want to own La Jolla’s assets. La Jolla already has multiple regulatory wins under its belt. In 2017, the Food and Drug Administration (FDA) approved GIAPREZA , La Jolla’s lead product, to increase blood pressure in adults with septic or other distributive shock. Also, in 2018 the FDA approved La Jolla subsidiary Tetraphase’s XERAVA to treat complicated intra-abdominal infections in patients 18 years of age and older. Thus, acquiring La Jolla Pharmaceutical will help Innovia strengthen its infectious-diseases portfolio. Apparently, Innovia was already moving in this direction through its recent purchase of Entasis Therapeutics, which develops novel antibacterial products.

Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022.

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Innoviva, Inc. (NASDAQ: INVA).

Innoviva Inc (NASDAQ: INVA ) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis'' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire … Full story available on Benzinga.com

GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%.